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Abstract 
Oral non-Hodgkin’s lymphomas (O-NHLs)  are a rare group of diverse lymphoid tissue malignancies and represent 
less than 5% of the oral cavity malignancies and 2% of all extra-nodal NHLs. Oral-NHLs affect the Waldeyer’s-
ring, the salivary glands, the bone of the jaws and the oral mucosa, their clinical appearance is very heterogeneous. 
Among the risk factors for NHLs are immunosuppression (primary or secondary), autoimmunity and inflammation. 
O-NHLs share the same risk factors. This case report describes a patient with O-NHL which was possibly linked 
to the combination of methotrexate and etanercept for the treatment of her rheumatoid arthritis. To our knowledge 
this is probably among the first cases of O-NHL with possible relation to the use of a Tumor Necrosis Factor (TNF) 
antagonist biological agent (etanercept). This case could contribute to the sensitization of the dentists for the signs 
and symptoms of this rare malignancy. It also underlines the need for thorough medical history and medication 
recording for all the dental patients.
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Introduction
Non-Hodgkin’s lymphomas [NHLs] are a heterogeneous 
group of lymphoid tissue malignancies accounting for 
at least 61 types of NHLs [WHO 2008 classification] 
(1). NHL has nearly doubled its incidence over the last 
40 years becoming the fifth most common cancer (2,3). 
Lymphomas can occur outside the lymphatic system. 
The most common tissues of extra-lympatic/ extra-nodal 
origin are the mucosae [MALT lymphomas] especially 
of the gasrtointestinal tract and the skin [cutaneous lym-
phomas]. Extra-nodal involvement is identified in 30% of 
NHL cases (4). The NHL involvement in the oral cavity 
represents the 2% of cases that occur in an extra-nodal 
environment and is the 3rd most common oral cancer (5), 
but accounts for less than 5% of oral cancers, as approxi-
mately 90% of oral cancers are squamous cell carcinomas 
(6). NHLs in the oral cavity may affect sites where lym-
phoid tissue is present [tonsils, Waldeyer’s ring], the ma-
jor salivary glands, the jaws and also the oral mucosa (6).
The possibility for NHL increases as a result of uncom-
mon immune-disorders such as hereditary disorders of 
immune dysfunction, HIV/AIDS, and organ transplan-
tation, while other well-known risk factors comprise, 
infectious agents, a familial trait and autoimmune di-
sorders (7). Also there is a reported higher risk of lym-
phomas in patients treated with immune-modulating 
e181
J Clin Exp Dent. 2015;7(1):e180-2. Oral non-Hodgkin’s lymphoma possibly related to etanercept and methotrexate
sorder  of the oral soft tissue due to immune suppression. 
An immediate soft tissue biopsy [from the palatal surfa-
ce] and orthopantomography were performed. The ra-
diographic findings showed normal bone underneath the 
ulcer. The histological examination revealed lympho-
cytic infiltrate in hematoxylin eosin stain (Fig. 2), and a 
panel of immunohistochemistry markers for lymphoma 
revealed positivity for the CD30 [cluster of differentia-
tion (Fig. 2) and Epstein–Barr virus encoded early RNA 
[EBER]. These findings were considered suggestive for 
B-cell origin NHL or lymphomatoid granulomatosis be-
cause of the presence of areas with angiocentric local 
allocation. Further molecular tests were scheduled [po-
lymerase chain reaction [PCR]] and revealed monoclo-
nal B-cell population among the lymphocytic infiltrate 
so, the final diagnosis was B-cell origin NHL.
The patient was referred to a tertiary oncology and hema-
tology clinic [Laiko Hospital, Athens Greece] and was in-
vestigated with PET-scan [Positron emission tomography] 
and CT [Computed tomography], which showed that the 
only site affected was the oral mucosa. She was also eva-
luated by a Rheumatologist. Both the Hematologist and 
Rheumatologist in charge considered that her NHL was 
possibly related to the use of etanercept and secondary to 
methotrexate so they stopped her of the agents. The patient 
was treated with a combination of the anti-CD20 mono-
clonal antibody rituximab [Rituximab 1000mg / 6 months] 
and classic CHOP [Cytoxan, Hydroxyrubicin [Adriamy-
cin], Oncovin [Vincristine], Prednisone],chemotherapy 
regimen. Three years after the initial diagnosis she is free 
of disease (Fig. 1), and her rheumatoid arthritis is contro-
lled only with low dose prednisolone.
Discussion
Despite the fact that etanercept has been labeled with a 
risk for NHL, the connection between the drug and the 
disease is still questionable (9). In our case the patient 
had an excellent response and we could not ignore the 
fact that her response may be related to the cessation of 
etanercept, a clinical observation reported in the literatu-
re (10). In addition, the fact that etanercept was combi-
Fig. 1. The initial appearance of the patient in May 2011 could represent an ulceration of various causes. Three years after diagnosis she is 
disease free. Note that she has inflammation on the buccal gingival area of #26 as she is reluctant to thoroughly brush this tooth. A) Buccal 
surface of Patient May 2011;  B) Palatal surface of Patient May 2011;  C) Buccal surface of Patient May 2014;  D) Palatal surface of Patient 
May 2014.
agents (7). Among these agents biologic agents blocking 
the function of Tumor Necrosis Factor [TNF], include 
among their  [U.S. Food and Drug Administration] FDA 
and [European Medicines Agency] EMEA registered 
side effects a risk for malignant lymphoma development, 
notably of uncommon NHL types (8). Etanercept is a 
fusion protein resembling TNF receptors type-II, which 
acts by blocking circulating TNF and lymphotoxin-a (8). 
It is approved for the treatment of Rheumatoid arthritis, 
Psoriatic arthritis, Ankylosing spondylitis, Moderate to 
severe plaque psoriasis and Severely active polyarticu-
lar juvenile idiopathic arthritis in children aged 2 years 
and older (8). Cases of lymphomas have been reported 
in adult patients with Rheumatoid arthritis and children 
with Juvenile idiopathic arthritis (9), and the FDA added 
a black box label for this reason, but still questions re-
main whether etanercept  risk for NHL is higher than 
that attributed to the underlying disease used for (9).
Case Report
In this article we report a case of a 60 year old female 
patient with a ten year history of Rheumatoid arthritis 
treated with prednisolone 10mg/ daily, methotrexate 
10mg /week, etanercept 25mg/weekly [for more than 
a year] and also risedronate sodium 35mg /weekly for 
prevention of osteoporosis. The main complaint of the 
patient was an ulcer with a 3 weeks reported duration, 
which caused moderate constant pain. She had done a 
full blood count and biochemical panel which showed 
no abnormal findings. She initially visited for this rea-
son a general dentist who prescribed fluconazole and as 
the lesion did not resolve, she consulted an oral surgeon 
who suggested evaluation by an oral medicine specialist. 
The clinical examination revealed an ulcer with irregu-
lar margins covered with necrotic slough, located on the 
gingiva of the upper left quadrant [#25,#26], where the 
patient had an old bridge, (Fig. 1) and extended from the 
buccal to palatal surface. She had no palpable neck lym-
ph nodes. According to the medical history and clinical 
findings the differential diagnosis, was : osteonecrosis, 
ulceration due to methotrexate, lymphoproliferative di-
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ned with methotrexate, another agent linked to NHL risk 
[especially those related to Epstein–Barr virus] enhan-
ces the possibility that her NHL is rather related to her 
long term immunosuppressive therapy rather than her 
disease (7). To our knowledge this is among the first [if 
not the first] reported cases of O-NHL possibly related 
to etanercept or other anti-TNF agent (11). Patients with 
autoimmune diseases and long term immunosuppres-
sion should be informed to report their medical history 
to their dentist and the dentist should check their mouth 
for any unusual lumps or ulcers, as the clinical appearan-
ce of O-NHLs is highly atypical (6). The physical exam 
should be completed with palpation of neck nodes. Any 
abnormal findings should be carefully evaluated. The 
fact the patient’s dentist and oral surgeon did not attempt 
any extraction or periodontal surgery and suspected a 
non dental or periodontal cause for her ulcer contributed 
significantly to her excellent outcome (12).
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